ArticleCEN case reports2026
Clinical and genetic diagnosis of a patient with focal segmental glomerulosclerosis due to a novel variant of the ANLN gene.
Article in CEN case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Focal segmental glomerulosclerosis (FSGS), a common cause of nephrotic syndrome, is diagnosed by renal biopsy showing focal segmental sclerosis with foot-process effacement. It has a poor prognosis and can rapidly progress to end-stage kidney disease (ESKD). While the etiology of FSGS is largely unknown, many genes have been linked to the familial form of the condition. One of its subtypes, FSGS8, is caused by a heterozygous mutation in the ANLN gene on chromosome 7p14. However, reports of disease-causing ANLN variants in the literature are scarce. Here, we report a novel variant of ANLN in a Chinese family with FSGS. The proband was in hospital for proteinuria and the laboratory tests elevated levels of serum creatinine and uric acid. Histopathology study of renal biopsy showed FSGS. Genetic testing based on whole-exome sequencing (WES) was performed to explore the molecular basis. A heterozygous pathogenic variant of the ANLN gene, NM_018685 c.2343G > C, was identified in the affected patients and further confirmed by Sanger sequencing. This variant leads to a missense mutation in the anillin protein, altering its structure. This novel pathogenic variant of the ANLN gene provides a molecular basis for FSGS8 and expands the known mutation spectrum for FSGS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.